The Food and Drug Administration (FDA) announced it will hold a meeting this summer to evaluate the regulatory status of over half a dozen peptide injections, substances often promoted for muscle building, injury healing, and anti-aging. These peptides, while gaining popularity among influencers, fitness advocates, and celebrities, largely lack comprehensive safety and efficacy evidence, raising concerns among medical professionals and regulators.

The upcoming review responds to calls from Health Secretary Robert F. Kennedy Jr., who has publicly supported loosening restrictions on peptides, citing personal benefits and highlighting the proliferation of unregulated products. The FDA plans to consult external advisory panels to decide whether these peptides can be safely produced by pharmacies, potentially removing them from high-risk drug classifications. Critics, including former FDA officials and health scientists, warn that easing such controls could threaten decades of drug safety standards and open the floodgates to unvetted, potentially harmful products in the marketplace.

Despite FDA warnings about risks like cancer and organ damage, the peptides remain popular in wellness and supplement markets, with some being illegally marketed and used for doping in sports. The controversy reflects broader debates over regulatory oversight, supplement safety, and the influence of celebrity endorsements on health practices.